Randomized trials in exocrine pancreatic cancer

Ake Andrén-Sandberg; Mats Hedberg; Katarzyna Winter; Ewa Małecka-Panas

doi:10.5114/pg.2011.21718

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2011
vol. 6

Send email

Copy url:

abstract:

Review paper

Randomized trials in exocrine pancreatic cancer

Ake Andrén-Sandberg

,

Mats Hedberg

,

Katarzyna Winter

,

Ewa Małecka-Panas

Przegląd Gastroenterologiczny 2011; 6 (2): 85–96

DOI: https://doi.org/10.5114/pg.2011.21718

Online publish date: 2011/04/29

View full text Get citation

PlumX metrics:

Treatment of pancreatic cancer is a major oncological challenge. Pancreatic cancer remains a highly lethal disease and is the 4th leading cause of cancer-related deaths in the United States, with a 5-year survival of less than 5%. The poor prognosis of this cancer is due to its propensity for early local invasion and metastasis. Most patients present with advanced disease, precluding curative surgical resection, which remains the only potential curative approach. The adjuvant treatment may improve the prognosis in pancreatic cancer. This article presents a review of randomized clinical trials including adjuvant and neoadjuvant treatment, monotherapy and combination therapy, pain relief and the role of nutrition in pancreatic cancer treatment.

keywords:

Randomized trials in exocrine pancreatic cancer

Ake Andrén-Sandberg , Mats Hedberg , Katarzyna Winter , Ewa Małecka-Panas

pancreatic cancer, adjuvant treatment, neoadjuvant treatment, chemotherapy, chemoradiotherapy, gemcitabine

Ake Andrén-Sandberg

,

Mats Hedberg

,

Katarzyna Winter

,

Ewa Małecka-Panas